SBIR-STTR Award

Transgenic Chickens using Primordial Germ Cells
Award last edited on: 6/5/09

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$943,359
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Mariececile Vandelavoir

Company Information

Origen Therapeutics Inc

5885 Hollis Street Suit 165
Emeryville, CA 94608
   (510) 597-5140
   info@origentherapeutics.com
   www.origentherapeutics.com
Location: Multiple
Congr. District: 13
County: Alameda

Phase I

Contract Number: 1R43GM073306-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2005
Phase I Amount
$114,657
The aim of this research is to establish a cell line from chicken primordial germ cells that retains it potential to contribute to the germline with the goal of developing genetically modified chickens that produce pharmaceutical proteins in their eggs. Primordial germ cells obtained from the blood and the gonads can be cultured and retain their ability to contribute to the germline when injected into the bloodstream of stage 14-17 chicken embryos. However, only short periods of mixed cultures have been reported and the number of cells that have been generated is too small to be used for the production of transgenic chickens. If PGCs can be cultured and expanded for longer periods of time to achieve stable integration of transgenes while maintaining their competency to colonize the germline, it would provide a novel and reliable route to germline transmission. This application proposes to obtain PGCs from the germinal crescent to obtain a pure population of PGCs and to culture the PGCs under various conditions to obtain a cell line that retains the potential to contribute to the germline after injection into the bloodstream of a stage 14-16 (H&H) embryo

Phase II

Contract Number: 5R44GM073306-03
Start Date: 3/1/05    Completed: 5/31/09
Phase II year
2007
Phase II Amount
$828,702
Origen Therapeutic's goal is to develop chickens that produce fully human monoclonal and polyclonal antibodies. To achieve this aim the chicken Origen needs the capability to insert and modify the chicken genome and to transmit these genomic modifications through the germline. Origen's platform centers around a cell based system that allows integration of large pieces of DNA and allows precise deletions in the genome. To this end Origen has identified a cell population that has the potential to enter the germline. This application focuses on transfecting this cell population with large (150 kb) constructs and to knock-out specific genes within the chicken genome. These transfected cell popupations will then be trafficked through the germline to obtain a flock of transgenic chickens.

Public Health Relevance:
This Public Health Relevance is not available.

Thesaurus Terms:
Antibody, Chicken, Genetically Modified Animal, Immunologic Substance Development /Preparation, Method Development, Monoclonal Antibody, Pluripotent Stem Cell Chimeric Protein, Developmental Genetics, Immunoglobulin, Nonmammalian Vertebrate Embryology Bioengineering /Biomedical Engineering, Immunotherapy, Site Directed Mutagenesis, Transfection, Transposon /Insertion Element